Venetoclax and Azacitidine in the Treatment of Patients with Relapsed/Refractory Myelodysplastic Syndrome

被引：13
|
作者：
Zeidan, Amer M. [1 ,2 ]
Borate, Uma [3 ]
Pollyea, Daniel A. [4 ]
Brunner, Andrew M. [5 ]
Roncolato, Fernando [6 ]
Garcia, Jacqueline S. [7 ]
Filshie, Robin J. [8 ]
Odenike, Olatoyosi [9 ,10 ]
Watson, Anne-Marie [11 ]
Krishnadasan, Ravi [12 ]
Bajel, Ashish [13 ,14 ]
Naqvi, Kiran [15 ]
Zha, Jiuhong [16 ]
Hogdal, Leah [16 ]
Zhou, Ying [16 ]
Hoffman, David [16 ]
Kye, Steve [16 ]
Garcia-Manero, Guillermo [17 ]
机构：
[1] Yale Univ, Sch Med, Dept Internal Med, Sect Hematol, New Haven, CT 06510 USA
[2] Yale Canc Ctr, New Haven, CT USA
[3] Oregon Hlth & Sci Univ, Div Hematol & Med Oncol, Knight Canc Inst, Portland, OR 97201 USA
[4] Univ Colorado, Dept Hematol, Aurora, CO USA
[5] Massachusetts Gen Hosp, Ctr Leukemia, Boston, MA 02114 USA
[6] Univ New South Wales, Dept Hematol, Sydney, NSW, Australia
[7] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA
[8] St Vincents Hosp Melbourne, Dept Hematol, Melbourne, Vic, Australia
[9] Univ Chicago Med, Chicago, IL USA
[10] Comprehens Canc Ctr, Chicago, IL USA
[11] Liverpool Hosp, Dept Haematol, Liverpool, Merseyside, Australia
[12] Univ Arizona, Canc Ctr, Tucson, AZ USA
[13] Peter MacCallum Canc Ctr, Dept Clin Haematol, Melbourne, Vic, Australia
[14] Royal Melbourne Hosp, Melbourne, Vic, Australia
[15] Genentech Inc, San Francisco, CA 94080 USA
[16] AbbVie Inc, N Chicago, IL USA
[17] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA
来源：
BLOOD | 2021年 / 138卷
关键词：
D O I：
10.1182/blood-2021-145646
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
537
引用
收藏
页数：6
相关论文
共 50 条
  • [21] Single-center pediatric experience with venetoclax and azacitidine as treatment for myelodysplastic syndrome and acute myeloid leukemia
    Winters, Amanda C.
    Maloney, Kelly W.
    Treece, Amy L.
    Gore, Lia
    Franklin, Anna K.
    PEDIATRIC BLOOD & CANCER, 2020, 67 (10)
  • [22] Prediction of Volasertib Sensitivity in Acute Myeloid Leukemia Relapsed or Refractory to Venetoclax Plus Azacitidine
    Patil, Lokesh
    Gu, Christine J.
    Tognon, Cristina
    Long, Nicola
    Johnson, Kara
    Fischer, Melissa A.
    Ball, Somedeb
    Savona, Michael R.
    Leonardi, Chris
    Wagner, Joseph
    Michelson, Glenn
    Lacher, Markus D.
    BLOOD, 2024, 144 : 5818 - 5819
  • [23] Venetoclax Combined with Azacitidine and Homoharringtonine in Relapsed/Refractory AML: A Multicenter, Phase 2 Trial
    Hua Jin
    Yu Zhang
    Sijian Yu
    Xin Du
    Na Xu
    Ruoyang Shao
    Dongjun Lin
    Yanqiu Chen
    Jie Xiao
    Zhiqiang Sun
    Lan Deng
    Xinquan Liang
    Hongyu Zhang
    Ziwen Guo
    Min Dai
    Pengcheng Shi
    Fen Huang
    Zhiping Fan
    Zhao Yin
    Li Xuan
    Ren Lin
    Xuejie Jiang
    Guopan Yu
    Qifa Liu
    Journal of Hematology & Oncology, 16
  • [24] Venetoclax Combined with Azacitidine and Homoharringtonine in Relapsed/Refractory AML: A Multicenter, Phase 2 Trial
    Jin, Hua
    Zhang, Yu
    Yu, Sijian
    Du, Xin
    Xu, Na
    Shao, Ruoyang
    Lin, Dongjun
    Chen, Yanqiu
    Xiao, Jie
    Sun, Zhiqiang
    Deng, Lan
    Liang, Xinquan
    Zhang, Hongyu
    Guo, Ziwen
    Dai, Min
    Shi, Pengcheng
    Huang, Fen
    Fan, Zhiping
    Yin, Zhao
    Xuan, Li
    Lin, Ren
    Jiang, Xuejie
    Yu, Guopan
    Liu, Qifa
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2023, 16 (01)
  • [25] Role of Venetoclax in the Treatment of Relapsed and Refractory Multiple Myeloma
    Ehsan, Hamid
    Wahab, Ahsan
    Shah, Zunairah
    Sana, Muhammad Khawar
    Masood, Adeel
    Rafae, Abdul
    Hashmi, Hamza
    JOURNAL OF HEMATOLOGY, 2021, 10 (03) : 89 - 97
  • [26] ORAL RIGOSERTIB COMBINED WITH AZACITIDINE IN PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) AND MYELODYSPLASTIC SYNDROMES (MDS): EFFECTS IN TREATMENT NAIVE AND RELAPSED/REFRACTORY PATIENTS
    Navada, S.
    Garcia-Manero, G.
    Hearn, K.
    Odchimar-Reissig, R.
    Demakos, E.
    Fenaux, P.
    Petrone, M.
    Zbyszewski, P.
    Fruchtman, S.
    Silverman, L.
    HAEMATOLOGICA, 2017, 102 : 183 - 184
  • [27] Azacitidine-venetoclax versus azacitidine salvage treatment for primary induction failure or first relapsed acute myeloid leukaemia patients
    Petit, C.
    Saillard, C.
    Mohty, B.
    Hicheri, Y.
    Villetard, F.
    Maisano, V.
    Charbonnier, A.
    Rey, J.
    D'Incan, E.
    Rouzaud, C.
    Gelsi-Boyer, V.
    Murati, A.
    Lhoumeau, A. C.
    Ittel, A.
    Mozziconacci, M. J.
    Alary, A. S.
    Hospital, M. -A.
    Vey, N.
    Garciaz, S.
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2024, 112 (04) : 530 - 537
  • [28] EFFICACY OF VENETOCLAX/AZACITIDINE SALVAGE THERAPY COMPARED TO AZACITIDINE MONOTHERAPY FOR PATIENT WITH FIRST RELAPSED OR REFRACTORY ACUTE MYELOID LEUKAEMIA
    Petit, C.
    Mohty, B.
    Hicheri, Y.
    Saillard, C.
    Villetard, F.
    Maisano, V.
    Charbonnier, A.
    Rey, J.
    D'Incan, E.
    Vey, N.
    Hospital, M. -A.
    Garciaz, S.
    ANNALS OF HEMATOLOGY, 2023, 102 (SUPPL 1) : S53 - S54
  • [29] Azacitidine for Treatment of Therapy Related Myelodysplastic Syndrome
    Komrokji, Rami S.
    Al Ali, Najla H.
    Alrawi, E.
    Padron, Eric
    Perkins, Janelle
    Field, Teresa
    Lancet, Jeffrey E.
    List, Alan F.
    BLOOD, 2011, 118 (21) : 745 - 746
  • [30] Treatment outcome of 5′-azacitidine for myelodysplastic syndrome
    Kim, Y. K.
    Kim, H. J.
    Song, J. E.
    Kim, S. E.
    Ahn, J. S.
    Yang, D. H.
    Lee, J. J.
    LEUKEMIA RESEARCH, 2013, 37 : S110 - S110
12345